Cancer Neuroscience Symposium 2024
Wednesday, February 28, 2024, 1:00 PM – Friday, March 1, 2024, 4:00 PM
MD Anderson, Houston, TX
MD Anderson Cancer Center presents a two-day hybrid symposium featuring contributions from over 30 leading international experts focused on Cancer Neuroscience. Be part of a groundbreaking scientific event that will integrate neuroscience, cancer biology and aging science to spur a wave of innovation in cancer research and care. Building on our previous meeting with over 1200 participants as well as collaborative research and discussion among our speakers,
the goal of this meeting is to explore how the interface between cancer biology and neuroscience impacts tumor development, progression and health outcomes.
This 2nd Cancer Neuroscience Symposium will leverage advances in neuroscience, as well as advances in immuno-oncology and aging. This meeting will cover emerging areas, such as neuro-immune interactions, plasticity within the tumor microenvironment, and translational research. This meeting will bring together leading experts from across the fields of neuroscience, cancer biology, immunology, and the biology of aging, as well as oncologists, surgeons, neurologists, patients and patient advocates to facilitate discussions of exciting new concepts and developments in this rapidly growing field.
CNS 2024: Satellite Meeting on Clinical Cancer Neuroscience
The 2024 Satellite Meeting of the Cancer Neuroscience Symposium will be held virtually on February 28, 2024. Talks will present translational and clinical innovations in cancer neuroscience. Speakers will discuss advances in neurotoxicities during cancer therapies, mental health and pain effects from cancer and cancer therapies, a clinical trial panel, and a meet the editor session. The satellite meeting aims to cross-fertilize the breadth of cancer neuroscience presented at the primary cancer neuroscience symposium.
Additional Information & Registration
Midwestern Women In Otolaryngology Symposium
Eric P. Newman Education Center @ Washington University Medical Center
St. Louis, MO United States
March 1, 2024 12:00 PM – 7:00 PM
Additional Information and Registration
Harvard Medical School
Technology and Innovation in Endocrine Head and Neck Surgery
March 22-23, 2024 | In-Person | Register Today
Head and neck endocrine and oncologic surgery continues to evolve through technological advancements and innovation. Optimized nerve identification and preservation has been facilitated through advancements in nerve monitoring technology and techniques. Novel methods of tissue differentiation using techniques such as autofluorescence, labeled fluorescence, optical coherence tomography and others may improve ability to identify and characterize nerves, parathyroid tissue and tumor margins, among other applications. Application of minimally invasive ablative therapies is shifting the landscape of treatment for thyroid nodules.
This 1.5-day course will cover:
RFA
Neural monitoring state of the art/SLN and continuous monitoring and neural anatomy
Ultrasound and AI
Parathyroid autofluorescence probe and camera based systems and ICG
Neural RLN intraop imaging
Optical Coherence intraop imaging
Parathyroid vascular imaging
State of the art imaged based margin assessment
The course is designed for clinicians, surgeons and researchers alike who have an interest in developing and applying innovative technologies to augment care for head and neck endocrine disorders. The course will also offer an optional hands-on practical component for learners to participate in radiofrequency ablation (RFA) using phantom models (space limited).
Faculty
Technology and Innovation in Endocrine Head and Neck Surgery features Harvard Medical School faculty and prominent experts and leaders in their field.
The course is led by:
Gregory W. Randolph, MD, FACS, FACE
Marika Russell, MD, FACS
Accreditation
In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Harvard Medical School designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Information & Register Today
Harvard Medical School
Surgery of the Thyroid and Parathyroid Glands
November 15-16, 2024 | In Person: Boston, MA
Register Today
The field of thyroid and parathyroid surgery has recently undergone significant changes; thyroid cancer incidence has increased dramatically over the last several decades, technologic advances have been achieved in molecular analysis and development of targeted therapy, and thermal ablation of thyroid nodules has emerged as a promising treatment strategy. The American Thyroid Association is soon to publish a new set of medical and surgical thyroid nodule and thyroid cancer guidelines. There is a tremendous new data set that is important to convey to medical endocrinologists and thyroid and parathyroid surgeons.
This course is a 2-day course about surgery of the thyroid and parathyroid glands, which has been offered since 1996. Preoperative evaluation, management and surveillance of low-risk thyroid cancer will be reviewed. Contemporary management of advanced thyroid cancer will be covered, with topics ranging from neoadjuvant targeted therapy to surgical management of the invaded recurrent laryngeal nerve. Updates in the management of oncocytic carcinoma will be discussed. A debate will be held on thyroid ablation technology. The new Adult Complex Thyroid Surgery Focused Practice Designation will be reviewed. A range of topics in parathyroid disease will be covered, from preoperative localization to intraoperative use of autofluorescence to advances in long-acting PTH treatment for hypoparathyroidism. Panel discussions and a tumor board will highlight management options and challenges for thyroid and parathyroid conditions.
This course is targeted to Specialty Physicians.
Faculty:
Surgery of the Thyroid and Parathyroid Glands features Harvard Medical School faculty and prominent experts and leaders in their field.
Course Directors:
Gregory Randolph, MD, FACS, FACE
Marika Russell, MD, FACS
Carrie Cunningham, MD MPH
Objectives and Accreditation
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe contemporary management for low-risk thyroid cancer, including preoperative evaluation, surgical treatment, and postoperative surveillance.
- Acquire familiarity with new ATA guidelines on thyroid nodules and thyroid cancer.
- Explore recent advances the treatment of advanced thyroid cancer, including molecular analysis, neoadjuvant therapy, surgical management, and updates in pathologic classification.
- Discuss the advantages and limitations of various thermal ablation options for treatment of thyroid nodules and thyroid cancer.
- Develop and understanding of the new Adult Complex Thyroid Surgery Focused Practice Designation.
- Discuss preoperative evaluation of hyperparathyroidism, including localization studies and indications for surgery based on current guidelines.
- Evaluate the use of intraoperative parathyroid autofluorescence as an adjunctive surgical tool.
Accreditation
In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Harvard Medical School designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Visit our website for all credits available and additional details.